PMID- 14750934
OWN - NLM
STAT- MEDLINE
DCOM- 20040315
LR  - 20191108
IS  - 1351-8216 (Print)
IS  - 1351-8216 (Linking)
VI  - 9
IP  - 6
DP  - 2003 Nov
TI  - Successful treatment of urgent bleeding in von Willebrand disease with factor 
      VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) 
      to measure potency and to guide therapy.
PG  - 688-95
AB  - This prospective, open-label, non-randomized study evaluated the safety and 
      efficacy of factor VIII (FVIII)/von Willebrand Factor (VWF) concentrate 
      (Humate-P) using treatment regimens based on VWF:ristocetin cofactor (VWF:RCo) 
      activity in patients with von Willebrand Disease (VWD) in (i) urgent bleeding 
      episodes, or (ii) in patients undergoing urgent and necessary surgery. This 
      article summarizes the results of treatment for the 33 patients with 53 urgent 
      bleeding events. The median loading dose of FVIII/VWF concentrate was 67.0 
      international units per kilogram (IU kg(-1)) VWF:RCo (range 25.7-143.2 IU 
      kg(-1)), and the median daily maintenance dose per infusion was 74.0 IU kg(-1) 
      (range 16.4-182.9 IU kg(-1)) for a median duration of 2 days (range 1-34 days). 
      The overall efficacy (achievement of haemostasis) of FVIII/VWF concentrate was 
      rated as excellent/good for 98% of the urgent bleeding events. No unexpected 
      treatment-related adverse events or serious drug-related adverse events (AEs) 
      were observed. This study supports the safety and efficacy of Humate-P 
      administered in doses calculated in VWF:RCo units for the treatment of urgent 
      bleeding episodes in patients with VWD.
FAU - Gill, J Cox
AU  - Gill JC
AD  - Medical College of Wisconsin and The Blood Center, Milwaukee, WI Brigham and 
      Women's Hospital, Boston, MA Puget Sound Blood Center, Seattle, WA Aventis 
      Behring, King of Prussia, PA, USA.
FAU - Ewenstein, B M
AU  - Ewenstein BM
FAU - Thompson, A R
AU  - Thompson AR
FAU - Mueller-Velten, G
AU  - Mueller-Velten G
FAU - Schwartz, B A
AU  - Schwartz BA
CN  - Humate-P Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Haemophilia
JT  - Haemophilia : the official journal of the World Federation of Hemophilia
JID - 9442916
RN  - 0 (Coagulants)
RN  - 0 (von Willebrand Factor)
RN  - 9001-27-8 (Factor VIII)
SB  - IM
MH  - Coagulants/adverse effects/pharmacokinetics/*therapeutic use
MH  - Drug Evaluation
MH  - Factor VIII/adverse effects/pharmacokinetics/*therapeutic use
MH  - Female
MH  - Hemorrhage/*prevention & control
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - von Willebrand Diseases/blood/*drug therapy
MH  - *von Willebrand Factor
EDAT- 2004/01/31 05:00
MHDA- 2004/03/17 05:00
CRDT- 2004/01/31 05:00
PHST- 2004/01/31 05:00 [pubmed]
PHST- 2004/03/17 05:00 [medline]
PHST- 2004/01/31 05:00 [entrez]
AID - 816 [pii]
AID - 10.1046/j.1351-8216.2003.00816.x [doi]
PST - ppublish
SO  - Haemophilia. 2003 Nov;9(6):688-95. doi: 10.1046/j.1351-8216.2003.00816.x.